Mirae Asset Global Investments Co. Ltd. Sells 56,744 Shares of Privia Health Group, Inc. (NASDAQ:PRVA)

Mirae Asset Global Investments Co. Ltd. reduced its stake in shares of Privia Health Group, Inc. (NASDAQ:PRVA) by 25.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 167,498 shares of the company’s stock after selling 56,744 shares during the quarter. Mirae Asset Global Investments Co. Ltd. owned about 0.14% of Privia Health Group worth $3,857,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of PRVA. ProShare Advisors LLC purchased a new position in shares of Privia Health Group during the first quarter valued at about $210,000. JPMorgan Chase & Co. boosted its stake in Privia Health Group by 60.3% during the first quarter. JPMorgan Chase & Co. now owns 33,839 shares of the company’s stock valued at $905,000 after buying an additional 12,732 shares during the last quarter. US Bancorp DE grew its holdings in Privia Health Group by 8.8% during the 1st quarter. US Bancorp DE now owns 13,923 shares of the company’s stock valued at $372,000 after buying an additional 1,131 shares in the last quarter. MetLife Investment Management LLC increased its stake in Privia Health Group by 200.9% in the 1st quarter. MetLife Investment Management LLC now owns 23,742 shares of the company’s stock worth $635,000 after acquiring an additional 15,852 shares during the last quarter. Finally, Rhumbline Advisers raised its holdings in shares of Privia Health Group by 124.7% during the 1st quarter. Rhumbline Advisers now owns 36,873 shares of the company’s stock worth $986,000 after acquiring an additional 20,464 shares in the last quarter. Institutional investors own 94.48% of the company’s stock.

Insider Transactions at Privia Health Group

In other news, CFO David Mountcastle sold 3,933 shares of Privia Health Group stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an average price of $17.77, for a total transaction of $69,889.41. Following the completion of the sale, the chief financial officer now owns 262,279 shares of the company’s stock, valued at $4,660,697.83. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Privia Health Group news, CFO David Mountcastle sold 3,933 shares of the firm’s stock in a transaction on Tuesday, April 2nd. The stock was sold at an average price of $17.77, for a total transaction of $69,889.41. Following the transaction, the chief financial officer now directly owns 262,279 shares in the company, valued at approximately $4,660,697.83. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director William M. Sullivan sold 9,951 shares of Privia Health Group stock in a transaction on Wednesday, January 24th. The shares were sold at an average price of $23.03, for a total value of $229,171.53. Following the sale, the director now directly owns 5,464,533 shares of the company’s stock, valued at $125,848,194.99. The disclosure for this sale can be found here. Corporate insiders own 14.20% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on PRVA. Truist Financial cut their target price on shares of Privia Health Group from $32.00 to $28.00 and set a “buy” rating for the company in a report on Thursday, February 29th. UBS Group dropped their price objective on shares of Privia Health Group from $31.00 to $29.00 and set a “buy” rating for the company in a research note on Friday, March 1st. Canaccord Genuity Group decreased their target price on shares of Privia Health Group from $41.00 to $37.00 and set a “buy” rating on the stock in a research report on Tuesday, March 19th. Evercore ISI lowered their price target on shares of Privia Health Group from $26.00 to $25.00 and set an “outperform” rating for the company in a report on Wednesday, February 28th. Finally, JPMorgan Chase & Co. reduced their price objective on Privia Health Group from $38.00 to $30.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 6th. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $28.18.

Privia Health Group Stock Down 3.6 %

PRVA stock opened at $17.69 on Wednesday. Privia Health Group, Inc. has a twelve month low of $17.54 and a twelve month high of $30.15. The firm has a market cap of $2.10 billion, a price-to-earnings ratio of 93.11, a PEG ratio of 2.53 and a beta of 0.81. The business’s fifty day simple moving average is $20.24 and its two-hundred day simple moving average is $21.49.

Privia Health Group (NASDAQ:PRVA) last posted its quarterly earnings results on Tuesday, February 27th. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.04 by ($0.02). Privia Health Group had a return on equity of 3.97% and a net margin of 1.39%. The company had revenue of $440.80 million during the quarter, compared to analysts’ expectations of $425.81 million. During the same period in the prior year, the business earned $0.14 EPS. The company’s quarterly revenue was up 21.0% on a year-over-year basis. Research analysts expect that Privia Health Group, Inc. will post 0.26 EPS for the current year.

Privia Health Group Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.